Associate Director of Lab Sciences, Dr. John Canfield participates in From Your Peers: Quantifying the Unseen: Tackling Low-Abundance Biomarkers with the Ella System

In today’s fast-moving therapeutic landscape, drug developers depend on accurate biomarker insights to guide decision-making from early discovery through late-stage clinical trials. For contract research organizations (CROs), delivering that data with speed, precision, and regulatory rigor is both a responsibility and a competitive edge.

Immunologix Laboratories, a specialized CRO based in the U.S., supports this mission by offering #GLP- and #GCP-compliant #biomarker and #bioanalytical services across a wide spectrum of modalities—from biologics and gene therapies to nucleic acid-based treatments.

At the helm of the biomarker division is John Canfield, PhD, Associate Director of Lab Sciences. Dr. Canfield leads a team responsible for shaping scientific strategy and managing operational execution across a broad portfolio of clinical programs. Whether supporting early-phase studies or large-scale trials, the team’s focus remains the same: delivering reliable, high-quality data that sponsors can trust.

Read ‘From your Peers: Quantifying the Unseen: Tackling Low-Abundance Biomarkers with the Ella System” here: https://eng2e.seismic.com/i/CGnd6UKYAkamHBxOv1hQegQp676XaI0oSFkFLYKbMWUjmqqju910TkVytf83t7Lqom3JwWAeQmXmG8qbBeJYqi___Dus40iBpikiqzpUe___hClK0Oo7tFjnI2flSlwdem2A